Peptide

MOTS-c analogs / MDP class talk

Also known as

MOTS-c analogs · CB4211 · CB-4211 · CB 4211 · mitochondrial-derived peptide class · MDP class · MDP peptides · MOTS-c derivatives · mitochondrial ORF peptide analogs · mitochondria based therapeutics · MBT peptides (CohBar) · CB5138 · CB5064 analogs · MBT5 analogs · MOTS-c analogue

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Class identity	Modified mitochondrial signaling peptides, with CB4211 the best-known clinical example. An unidentified analog is not automatically native MOTS-c or CB4211.
Why people search	Steadier energy, endurance, glucose handling and healthy aging. Most practical accounts concern native MOTS-c or mixed stacks rather than authenticated analog use.

Notes

MOTS-c analogs are modified mitochondrial signaling peptides, with CB4211 the best-known clinical example. People search this class for steadier energy, endurance, glucose handling and healthy aging. Most practical accounts describe native MOTS-c or mixed stacks; they do not show what an unidentified “analog” will do.

An analog changes the molecule. Native MOTS-c is a short signal linked to the mitochondria, the cell’s energy machinery. CB4211 was engineered from that signal. “Improved” does not mean interchangeable amounts, proven endurance gains or authenticated contents in a vendor vial. CohBar 2019 annual report (Official context · Accessed 2026-09-30)

Fat loss and glucose handling are less clear. Recomposition stories often include diet, training and other metabolic agents. A leaner appearance or “blood sugar feel” cannot establish insulin sensitivity. Analog-specific self-experiment evidence is much thinner than the native discussion.

Source context — CohBar 2019 annual report: Historical sponsor disclosure; pipeline aspirations are not community effects or current clinical availability.

What people notice

Native experiences	Users describe easier running, longer rides and more stamina or desk-work energy. Other runs bring no benefit, fading energy or lethargy during calorie restriction.
Fat and glucose claims	Diet, training and other metabolic agents accompany recomposition stories. Leaner appearance or a blood-sugar feeling does not measure insulin sensitivity.

Notes

Easier endurance and steadier energy. Native users describe longer rides, easier running or better gym stamina. One cyclist also reported less hunger and better desk-work energy after training. The same account mentioned significant lethargy while restricting calories; benefit and fatigue can coexist. Half life of Mots-C? (Personal report · Accessed 2026-09-30)

Same discussion, different responses. MESO users described 3–4 mg/week split three ways, or 5 mg three times weekly for six weeks then 10 mg weekly for four. Routes were unspecified. Energy improved in some runs, weakened in a later run, or never appeared; another user needed a four-hour nap with NAD. Mots-C hype, page 2 (Community discussion · Accessed 2026-09-30)

Source context — Half life of Mots-C?: Poster asking about a 10 mg injection is different from the endurance commenter; do not attach that dose to the ride report. No half-life value is established.

Source context — Mots-C hype, page 2: Native MOTS-c reports; routes are not supplied in the selected dose reports. Self-reported testing is not independently verified. #29 is a vendor promotional reply and is excluded.

Doses people talk about

Native weekly charts	SubQ charts describe 5–10 mg total/week, such as 5 mg once weekly or 2.5–5 mg twice weekly. Separate higher charts total 15 or 30 mg/week; they are not evidence that more works better.
Native daily charts	0.5–1 mg/day is a separate microdose pattern; weekday-only examples total 2.5–5 mg/week.
CB4211 trial context	25 mg SubQ daily for 28 days in a small clinical study. This is not a native or unidentified-analog chart; no transferable dose is established for an unknown derivative.

Notes

Native SubQ charts: 5–10 mg total per week. The original record describes 5 mg once weekly or 2.5–5 mg twice weekly beneath the skin. Daily microdose talk is separate: 0.5–1 mg per day; weekday-only examples total 2.5–5 mg per week. These are reported patterns, not instructions. The Ultimate Guide to MOTS-c | Topic Request Series (Community guide · Accessed 2026-09-30)

Higher charts disagree: 15 or 30 mg per week. The original 5 mg three-times-weekly chart totals 15 mg/week. A Reddit guide repeats a commercial clinic’s 10 mg SubQ three-times-weekly chart, totaling 30 mg/week. Neither establishes that more works better. The Ultimate Guide to MOTS-c | Topic Request Series (Community guide · Accessed 2026-09-30)

CB4211 trial: 25 mg SubQ daily for 28 days. Twenty participants completed assessment, 11 active and 9 placebo. Exploratory ALT, AST and glucose changes favored CB4211; liver-fat reductions were similar, 5.03 versus 4.88 percentage points. Safety was primary. This is not a native or mystery-analog dosing chart. CohBar August 10, 2021 investor presentation (Official context · Accessed 2026-09-30)

Unknown analog: no transferable dose. Native schedules cannot identify an unspecified derivative. HNG’s separate 0.5–2 mg SubQ daily culture in the original record is not a MOTS-c conversion. Morning, pre-training and fasting preferences also remain community practice.

Source context — The Ultimate Guide to MOTS-c | Topic Request Series: Guide repeats commercial peptide/clinic charts and overstates some animal findings. Selected comments are reports, not validated measurements. Collapsed replies, sourcing and mixing instructions excluded; relative dates left unspecified.

Source context — CohBar August 10, 2021 investor presentation: Sponsor-authored primary disclosure, not independent efficacy confirmation. Short controlled-diet study. Safety endpoint and exploratory effects must remain distinct.

Half-life, onset & duration

Felt onset	Native reports range from day one to the first week, with loss of early benefit also reported. Other saved accounts place subtler changes around weeks 1–2.
Felt duration	One native user felt good on the weekly administration day, less distinctly afterward; another lost running gains after stopping. No dependable single-dose or analog washout window emerges.
Half-life	No verified human injection value for native MOTS-c, CB4211 or an unnamed analog. A four-hour return toward baseline after exercise is not injected-peptide half-life.

Notes

First day to first week in native accounts; others notice nothing. An IM user reported energy on day one, then lost that benefit. A Reddit user noticed better energy after the first week while also using SS-31. The original record places subtler energy/training changes around weeks 1–2 and body-composition reassessment at weeks 4–8. Mots C Effects/Sides (Personal report · Accessed 2026-09-30) · Mots c: conflicting timing and stack reports (Secondhand community claim · Accessed 2026-09-30)

One good day does not establish a week of benefit. PepBoy described feeling good on the weekly administration day and less distinctly afterward. AgentSmith said running gains went away after stopping. Original accounts include fading over weeks, but no dependable single-dose benefit or analog washout window. MOTS-c Protocal (Community discussion · Accessed 2026-09-30) · Does anyone try MOTS-c? (Community discussion · Accessed 2026-09-30)

“4 hours” circulates; human injection clearance remains unknown. A Reddit poster challenges that number. A protocol-forum reply describes estimates from minutes to hours without human PK measurements. Neither gives a verified elimination half-life for native MOTS-c, CB4211 or an unnamed analog. Mots c: conflicting timing and stack reports (Secondhand community claim · Accessed 2026-09-30) · MOTS-c Protocal (Community discussion · Accessed 2026-09-30)

Four-hour exercise biology is not injected half-life. The human study measured naturally produced MOTS-c returning toward plasma baseline after exercise; injected performance experiments were in mice. ADDF’s September 2025 report says CB4211 development was discontinued. These findings do not validate gray-market human longevity claims. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Animal context · Accessed 2026-09-30) · MOTS-c Cognitive Vitality report (Official context · Accessed 2026-09-30)

Source context — Mots C Effects/Sides: Bodybuilding forum with vendor endorsements and other PED use. No measured glucose result establishes the cause of dizziness; route and diet changed together.

Source context — Mots c: conflicting timing and stack reports: Subreddit visibly promotes a community sponsor/affiliate program. Relative comment timestamps are not converted into exact dates. Four-hour claim is not a PK measurement.

Source context — MOTS-c Protocal: Protocol/vendor-index site with promotions; anonymous experiences and site-author opinion. No sequence authentication, human PK or proof of desensitization. Route unspecified by PepBoy.

Source context — Does anyone try MOTS-c?: Self-reports do not identify an analog exposure. Trial doses posted alongside a testimonial do not authenticate its vial. Buying/pricing replies excluded.

Source context — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis: Mixed human biomarker and mouse-treatment paper. Human participants exercised; they were not injected with MOTS-c. Full body accessible despite cookie-error query in final tool URL.

Source context — MOTS-c Cognitive Vitality report: Secondary review used only for its expressly attributed development-status report; primary study context comes from CohBar and Nature. No independent confirmation of corporate legal dissolution.

Cycles people discuss

Native blocks	Separate patterns include 4–8 weeks, or 8–12 weeks followed by 4–8 off. An 8-on/4-off chart describes 10 mg/week loading then 5 mg/week maintenance.
Native pulse	A copied 20-day chart uses four 5 mg SubQ administrations five days apart, 20 mg total, then months off. No best repeat interval is established.

Notes

4–8 weeks, or 8–12 weeks followed by 4–8 off. These are separate native patterns in the original record. An 8-on/4-off chart uses 10 mg/week loading followed by 5 mg/week maintenance. Continuous multi-month use also appears; breaks do not establish protection from harm or proven desensitization.

20-day pulse: four 5 mg SubQ administrations, five days apart. The copied chart totals 20 mg, followed by months off. It is a different pattern from weekly maintenance. Repeat courses around training or fat-loss blocks are reported, with no established best interval. The Ultimate Guide to MOTS-c | Topic Request Series (Community guide · Accessed 2026-09-30)

Stacks

SS-31 sequencing	SS-31 for 2–4+ weeks first, MOTS-c first, and concurrent blocks all appear. The proposed repair-plus-signal synergy has not been established by a combination trial.
Other metabolic stacks	HNG or SHLPs, NAD+/NMN/NR, GLP-1 drugs and SLU-PP-332 appear. Their schedules and effects are not interchangeable; stacking makes appetite or glucose-like symptoms harder to explain.
Native + unknown analog	Some accounts combine both without identifying the second vial; that adds another unresolved product identity.

Notes

SS-31 first, MOTS-c first or together? The original record describes SS-31 for 2–4+ weeks first, the reverse order and concurrent blocks. The hardware-repair/software-signal metaphor is a proposed mechanism, not combination-trial evidence. HNG, SHLPs, NAD+, NMN, NR, GLP-1 drugs and SLU-PP-332 add further attribution problems.

Special populations and stacks are unresolved. Pregnancy, serious illness and active-malignancy concerns lack a reliable community safety framework. Metabolic combinations complicate appetite and glucose-like symptoms. WADA’s 2026 list names MOTS-c among AMPK activators prohibited at all times. 2026 Prohibited List (Official context · Accessed 2026-09-30)

MDP pair / triad: MOTS-c-class + humanin/HNG (± SHLP2 footnotes) as multi-MDP “mito signal” suites. HNG daily mcg–mg culture is independent of MOTS-c weekly totals. [community]

Native + “analog” same block: Sometimes combined without clear identity of the second vial — unstudied and identity-risk compounding. [community]

Exercise-mimetic does not mean exercise replacement. Training, protein, sleep and calorie control remain part of the reported results. Native plus unidentified analog use compounds the identity problem. GLOW, KLOW and Wolverine recovery blends are a different discussion, not interchangeable mitochondrial-peptide programs.

Source context — 2026 Prohibited List: Sport rules do not establish toxicity or drug-test clearance times. No claim that every differently named MDP has identical classification.

Watch for

Reported discomfort	Sting, lasting bumps, fatigue, dizziness, headache, flushing, stomach upset, hunger, shaky feelings and fog appear in native accounts. Symptoms do not diagnose low glucose.
Identity and immune risks	The saved FDA review flags immune-reaction and impurity concerns for native MOTs-C. Native safety cannot be borrowed from CB4211, and an analog label does not authenticate a vial.
Unresolved populations and sport	Pregnancy, serious illness and active-malignancy concerns lack a reliable safety framework. The saved 2026 WADA list names MOTS-c among AMPK activators prohibited at all times.

Notes

Sting, bumps, fatigue and dizziness can outweigh the appeal. The original native record also includes headache, flushing, stomach upset, hunger, shaky feelings and brain fog or flat mood. Folate-cycle explanations for fog are speculation. Symptom reports do not diagnose low glucose or prove a particular interaction. The Ultimate Guide to MOTS-c | Topic Request Series (Community guide · Accessed 2026-09-30)

Convenience and discomfort change the verdict. PepBoy preferred weekly convenience but credited more frequent use with different training or body-composition effects. Peppers felt no benefit from three-times-weekly use and had a painful bump lasting days. A favorable schedule report does not settle the competing experiences. MOTS-c Protocal (Community discussion · Accessed 2026-09-30)

Native safety cannot be borrowed from CB4211. FDA identifies immune-reaction and peptide-impurity concerns for native MOTs-C. Gray-market identity and labeled milligrams remain uncertain; an “analog” label or testing claim does not establish equivalence to the trial molecule. Certain bulk drug substances that may present significant safety risks (Official context · Accessed 2026-09-30)

Source context — Certain bulk drug substances that may present significant safety risks: Agency statement concerns native MOTs-C compounded drug products, not proof that CB4211 never had human testing.

Source context — 2026 Prohibited List: Sport rules do not establish toxicity or drug-test clearance times. No claim that every differently named MDP has identical classification.

Full notes

What this class includes

An analog changes the molecule. Native MOTS-c is a short signal linked to the mitochondria, the cell’s energy machinery. CB4211 was engineered from that signal. “Improved” does not mean interchangeable amounts, proven endurance gains or authenticated contents in a vendor vial. Community Official context
MDP names cover different jobs. Humanin, HNG and SHLPs belong to the wider mitochondrial-derived peptide neighborhood. CB5064 apelin agonists, MBT5 CXCR4 antagonists and CB5138, also called MBT2, were separate experimental programs. Their cancer, fibrosis or metabolic research does not make them MOTS-c substitutes. Community Official context Animal context

What people hope to notice

Easier endurance and steadier energy. Native users describe longer rides, easier running or better gym stamina. One cyclist also reported less hunger and better desk-work energy after training. The same account mentioned significant lethargy while restricting calories; benefit and fatigue can coexist. Personal report
Fat loss and glucose handling are less clear. Recomposition stories often include diet, training and other metabolic agents. A leaner appearance or “blood sugar feel” cannot establish insulin sensitivity. Analog-specific self-experiment evidence is much thinner than the native discussion. Community Community

Doses people discuss

Native SubQ charts: 5–10 mg total per week. The original record describes 5 mg once weekly or 2.5–5 mg twice weekly beneath the skin. Daily microdose talk is separate: 0.5–1 mg per day; weekday-only examples total 2.5–5 mg per week. These are reported patterns, not instructions. Community Community guide
Higher charts disagree: 15 or 30 mg per week. The original 5 mg three-times-weekly chart totals 15 mg/week. A Reddit guide repeats a commercial clinic’s 10 mg SubQ three-times-weekly chart, totaling 30 mg/week. Neither establishes that more works better. Community Community guide
Unknown analog: no transferable dose. Native schedules cannot identify an unspecified derivative. HNG’s separate 0.5–2 mg SubQ daily culture in the original record is not a MOTS-c conversion. Morning, pre-training and fasting preferences also remain community practice. Community Community

Half-life

“4 hours” circulates; human injection clearance remains unknown. A Reddit poster challenges that number. A protocol-forum reply describes estimates from minutes to hours without human PK measurements. Neither gives a verified elimination half-life for native MOTS-c, CB4211 or an unnamed analog. Reddit Peptide Protocols forum
Frequent dosing is not a half-life measurement. The original record uses short-circulation lore to explain daily or multi-weekly schedules and longer downstream signaling. That reasoning does not prove how long the injected peptide stays in human blood. Community Community

Onset: when a change is noticed

First day to first week in native accounts; others notice nothing. An IM user reported energy on day one, then lost that benefit. A Reddit user noticed better energy after the first week while also using SS-31. The original record places subtler energy/training changes around weeks 1–2 and body-composition reassessment at weeks 4–8. Personal report Reddit Community

Duration: how long it lasts

One good day does not establish a week of benefit. PepBoy described feeling good on the weekly administration day and less distinctly afterward. AgentSmith said running gains went away after stopping. Original accounts include fading over weeks, but no dependable single-dose benefit or analog washout window. Peptide Protocols forum Rapamycin News Community

Cycles and time off

4–8 weeks, or 8–12 weeks followed by 4–8 off. These are separate native patterns in the original record. An 8-on/4-off chart uses 10 mg/week loading followed by 5 mg/week maintenance. Continuous multi-month use also appears; breaks do not establish protection from harm or proven desensitization. Community Community
20-day pulse: four 5 mg SubQ administrations, five days apart. The copied chart totals 20 mg, followed by months off. It is a different pattern from weekly maintenance. Repeat courses around training or fat-loss blocks are reported, with no established best interval. Community Community Community guide

Good to know

Sting, bumps, fatigue and dizziness can outweigh the appeal. The original native record also includes headache, flushing, stomach upset, hunger, shaky feelings and brain fog or flat mood. Folate-cycle explanations for fog are speculation. Symptom reports do not diagnose low glucose or prove a particular interaction. Community Community guide
Native safety cannot be borrowed from CB4211. FDA identifies immune-reaction and peptide-impurity concerns for native MOTs-C. Gray-market identity and labeled milligrams remain uncertain; an “analog” label or testing claim does not establish equivalence to the trial molecule. Official context Community
Special populations and stacks are unresolved. Pregnancy, serious illness and active-malignancy concerns lack a reliable community safety framework. Metabolic combinations complicate appetite and glucose-like symptoms. WADA’s 2026 list names MOTS-c among AMPK activators prohibited at all times. Community Official context

From community discussion

Same discussion, different responses. MESO users described 3–4 mg/week split three ways, or 5 mg three times weekly for six weeks then 10 mg weekly for four. Routes were unspecified. Energy improved in some runs, weakened in a later run, or never appeared; another user needed a four-hour nap with NAD. MESO-Rx
A route change does not isolate the cause. Scrut123 described 4–6 hours of dizziness after 1–1.5 mg IM pre-workout, then improvement after switching to 1 mg SubQ while adding training carbohydrates. Both changed together. Replies calling symptoms new mitochondria or low glucose did not measure either. Personal report
Convenience and discomfort change the verdict. PepBoy preferred weekly convenience but credited more frequent use with different training or body-composition effects. Peppers felt no benefit from three-times-weekly use and had a painful bump lasting days. A favorable schedule report does not settle the competing experiences. Peptide Protocols forum
SS-31 first, MOTS-c first or together? The original record describes SS-31 for 2–4+ weeks first, the reverse order and concurrent blocks. The hardware-repair/software-signal metaphor is a proposed mechanism, not combination-trial evidence. HNG, SHLPs, NAD+, NMN, NR, GLP-1 drugs and SLU-PP-332 add further attribution problems. Community
Exercise-mimetic does not mean exercise replacement. Training, protein, sleep and calorie control remain part of the reported results. Native plus unidentified analog use compounds the identity problem. GLOW, KLOW and Wolverine recovery blends are a different discussion, not interchangeable mitochondrial-peptide programs. Community

Supporting research context

CB4211 trial: 25 mg SubQ daily for 28 days. Twenty participants completed assessment, 11 active and 9 placebo. Exploratory ALT, AST and glucose changes favored CB4211; liver-fat reductions were similar, 5.03 versus 4.88 percentage points. Safety was primary. This is not a native or mystery-analog dosing chart. Official context
Persistent bumps belonged to the early formulation. CohBar attributed the 2018 pause to localized deposition and reported no persistent bumps after resuming with the revised formulation. Injection-site reactions remained in later safety reporting. Neither finding establishes long-term native tolerability. Official context Official context
Four-hour exercise biology is not injected half-life. The human study measured naturally produced MOTS-c returning toward plasma baseline after exercise; injected performance experiments were in mice. ADDF’s September 2025 report says CB4211 development was discontinued. These findings do not validate gray-market human longevity claims. Animal context Official context